Therapy of pulmonary involvement of rheumatic diseases;Therapie der lungenmanifestationen bei rheumatischen erkrankungen

Zeitschrift fur Rheumatologie

Volumn 62, Issue 1, 2003, Pages 10-15

  Graninger, Winfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Alveolitis; Cyclophosphamide; Endothelin receptor antagonists; Immunosuppression; Lung fibrosis; Prostacyclin; Pulmonary hypertension

Indexed keywords

BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; PROSTACYCLIN;

APHERESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LUNG BLOOD VESSEL; LUPUS ERYTHEMATOSUS; PARENCHYMA; PNEUMONIA; PROGNOSIS; PULMONARY HYPERTENSION; RHEUMATIC DISEASE; SCLERODERMA;

HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; PULMONARY FIBROSIS; RECEPTORS, ENDOTHELIN; RHEUMATIC DISEASES; VASODILATOR AGENTS;

EID: 0037325067     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-003-0478-y     Document Type: Article

References (84)

1. ASTIS: A multicenter, prospective randomized phase III study to compare efficacy and safety of high dose immunoablation and autologous hematopoietic stem cell transplantation with intravenous pulse therapy cyclophosphamide for the treatment of patients with severe systemic sclerosis. http://www astistrial com/ASTIShome HTM
2. AN 2002: The International Scleroderma network. http://www.sclero.org/medical/research/clinical-trials/open-enrollmen ts.html
3. Aringer M, Smolen JS, Graninger WB (1998) Severe infections in plasma-pheresis-treated systemic lupus erythematosus. Arthritis Rheum 41:414-420
4. Averbuch M, Halpern Z, Hallak A, Topilsky M, Levo Y (1985) Sulfasalazine pneumonitis. Am J Gastroenterol 80:343-345
5. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J (2002) Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 121:1860-1868
6. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, Guillevin L (2002) Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41:1126-1132
7. Belzunegui J, Intxausti JJ, De Dios JR, Lopez-Dominguez L, Queiro R, Gonzalez C, Figueroa M (2001) Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate. Clin Exp Rheumatol 19:727-730
8. Brunner M, Greinix HT, Redlich K, Knobl P, Smolen J, Leitner G, Derfler K, Graninger W, Kalhs P, Machold K (2002) Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: a case report. Arthritis Rheum 46:1580-1584
9. Burnouf C, Pruniaux MP (2002) Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 8:1255-1296
10. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, Rubin LJ (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119-1123
11. Chattaraj SC (2002) Treprostinil sodium Pharmacia. Curr Opin Investig Drugs 3:582-586
12. Cheema GS, Quismorio FP Jr (2000) Interstitial lung disease in systemic lupus erythematosus. Curr Opin Pulm Med 6:424-429
13. Chopra R, Radotra BD, Varma S, Gupta KL, Joshi K (1999) Acute pneumonitis with pulmonary hemorrhage an uncommon and potentially fatal complication of systemic lupus erythematosus: a case report. Indian J Pathol Microbiol 42:375-378
14. Coghlan JG, Mukerjee D (2001) The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology. Curr Opin Rheumatol 13:495-499
15. Cozzi PJ, Hall JB (1999) Cyclophosphamide in the treatment of pulmonary diseases: survey of use, training, and practitioner knowledge base. Chest 116:1159-1162
16. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18:455-461
17. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR (2002) Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 61:517-521
18. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP (2002) Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 41:262-267
19. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46:2294-2300
20. Dyke HJ, Montana JG (2002) Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 11:1-13
21. Eiser AR, Shanies HM (1994) Treatment of lupus interstitial lung disease with intravenous cyclophosphamide. Arthritis Rheum 37:428-431
22. Elborn JS, Conn P, Roberts SD (1987) Refractory massive pleural effusion in systemic lupus erythematosus treated by pleurectomy. Ann Rheum Dis 46:77-80
23. Erickson RW, Franklin WA, Emlen W (1994) Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum 24:114-123
24. Farre JM, Perez T, Hautefeuille P, Tonnel F, Colombel JF, Duquesnoy B, Delcambre B (1989) Cholestasis and pneumonitis induced by gold therapy. Clin Rheumatol 8:538-540
25. Farre JM, Perez T, Hautefeuille P, Tonnel F, Duquesnoy B, Delcambre B (1989) [Eosinophil pleuritis induced by salazosulfapyridine. Presse Med 18:987-988
26. Fukuda M, Kamiyama Y, Kawahara K, Kawamura K, Mori T, Honda M (1994) The favourable effect of cyclophosphamide pulse therapy in the treatment of massive pulmonary haemorrhage in systemic lupus erythematosus. Eur J Pediatr 153:167-170
27. Gallagher H, Kwan JT, Jayne DR (2002) Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis 39:42-47
28. Gamsu G, Webb WR (1978) Pulmonary hemorrhage in systemic lupus erythematosus. J Can Assoc Radiol 29:66-68
29. Garcia-Porrua C, Gonzalez-Gay MA, Perez de Llano LA, Alvarez-Ferreira J (1998) Fatal interstitial pneumonia due to cytomegalovirus following cyclophosphamide treatment in a patient with systemic lupus erythematosus. Scand J Rheumatol 27:465-466
30. Ghofrani H, Wiedemann R, Rose F, Schermuly R, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F (2002) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. 360:895-900
31. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, Fulminis A, De Luca A, Farina G, Candela M, Generini S, De Francisci A, Tirri E, Proietti M, Bombardieri S, Gabrielli A, Tonietti G, Cerinic MM (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29:731-736
32. Graninger M, Schmaldienst S, Derfler K, Graninger WB (2002) Immunoadsorption therapy (therasorb) in patients with severe lupus erythematosus. Acta Med Austriaca 29:26-29
33. Green RJ, Ruoss SJ, Kraft SA, Duncan SR, Berry GJ, Raffin TA (1996) Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management. Chest 110:1305-1316
34. Harmon KR, Leatherman JW (1988) Respiratory manifestations of connective tissue disease. Semin Respir Infect 3:258-273
35. Hoeper MM (2002) Pulmonary hypertension in collagen vascular disease. Eur Respir J 19:571-576
36. Huang DF, Tsai ST, Wang SR (1994) Recovery of both acute massive pulmonary hemorrhage and acute renal failure in a systemic lupus erythematosus patient with lupus anticoagulant by the combined therapy of plasmapheresis plus cyclophosphamide. Transfus Sci 15:283-288
37. Hubbard R, Venn A (2002) The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 41:676-679
38. Jackson G, Chambers J (2002) Sildenafil for primary pulmonary hypertension: short and long-term symptomatic benefit. Int J Clin Pract 56:397-398
39. Joseph J, Sahn SA (1993) Connective tissue disease and the pleura. Chest 104:262-270
40. Karim MY, Miranda LC, Tench CM, Gordon PA, D'cruz DP, Khamashta MA, Hughes GR (2002) Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus. Semin Arthritis Rheum 31:289-298
41. Keane MP, Lynch JP III (2000) Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 55:159-166
42. Khadadah ME, Jayakrishnan B, Al Gorair S, Al Mutairi M, Al Maradni N, Onadeko B, Malaviya AN (2002) Effect of methotrexate on pulmonary function in patients with rheumatoid arthri. Rheumatol Int 22:204-207
43. Kim NH, Rubin LJ (2002) Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J Cardiovasc Pharmacol Ther 7:9-19
44. Koh WH, Thumboo J, Boey ML (1997) Pulmonary haemorrhage in Oriental patients with systemic lupus erythematosus. Lupus 6:713-716
45. Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, Palmer WR, Sundy JS, St Clair EW, Alexander RW, Smith GJ, Axiotis CA (1997) Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 40:1829-1837
46. Lamblin C, Bergoin C, Saelens T, Wallaert B (2001) Interstitial lung diseases in collagen vascular diseases. Eur Respir J Suppl 32:69s-80s
47. Launay D, Hachulla E, Hatron PY, Goullard L, Onimus T, Robin S, Fauchais AL, Queyrel V, Michon-Pasturel U, Hebbar M, Saulnier F, Devulder B (2001) Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol 28:2252-2256
48. Lawry GV, Finerman ML, Hanafee WN, Mancuso AA, Fan PT, Bluestone R (1984) Laryngeal involvement in rheumatoid arthritis. A clinical, laryngoscopic, and computerized tomographic study. Arthritis Rheum 27:873-882
49. Lepore J, Maroo A, Pereira N, Ginns L, Dec G, Zapol W, Bloch K, Semigran M (2002) Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 90:677-680
50. Liu MF, Lee JH, Weng TH, Lee YY (1998) Clinical experience of 13 cases with severe pulmonary hemorrhage in systemic lupus erythematosus with active nephritis. Scand J Rheumatol 27:291-295
51. MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, Black, CM (2001) Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 40:453-459
52. Matsukawa Y, Saito O, Aoki M, Abe M, Nishinarita S, Sawada S, Horie T, Naruse S, Hiranuma M (2002) Long-term administration of beraprost, an oral prostacyclin analogue, improves pulmonary diffusion capacity in patients with systemic sclerosis. Prostaglandins Leukot Essent Fatty Acids 67:45-49
53. Mayordomo L, Marenco JL, Gomez-Mateos J, Rejon E (2002) Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol 31:44-45
54. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S (1999) Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 130:740-743
55. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, Mayes MD, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Ryan K, Sunderhaus J, Russell K, Rambharose J, Storb R, Furst DE (2002) High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100:1602-1610
56. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105:2398-2403
57. Murin S, Wiedemann HP, Matthay RA (1998) Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med 19:641-665, viii
58. Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoper MM, Behr J, Kleber FX, Seeger W (2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 132:435-443
59. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29:298-304
60. Parry SD, Barbatzas C, Peel ET, Barton JR (2002) Sulphasalazine and lung toxicity. Eur Respir J 19:756-764
61. Pass SE, Dusing ML (2002) Current and emerging therapy for primary pulmonary hypertension. Ann Pharmacother 36:1414-1423
62. Putterman C, Kramer M, Ben Chetrit E (1993) Pleurodesis for refractory pleural effusion in systemic lupus erythematosus. J Rheumatol 20:1990
63. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulldo T, Frost A, Roux S, Leconte I, Landzber, M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903
64. Saag KG, Kolluri S, Koehnke RK, Georgou TA, Rachow JW, Hunninghake GW, Schwartz DA (1996) Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 39:1711-1719
65. Saravanan V, Kelly CA (2002) Fibrosing alveolitis in patients with RA. Thorax 57:375-376
66. Schmeling H, Stephan V, Burdach S, Horneff G (2002) Pulmonary function in children with juvenile idiopathic arthritis and effects of methotrexate therapy. Z Rheumatol 61:168-172
67. Schnabel A, Reuter M, Gross WL (1998) Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 41:1215-1220
68. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800-804
69. Smolen JS (2002) Therapy of systemic lupus erythematosus: a look into the future. Arthritis Res 4 Suppl 3:S25-S30
70. Staudinger T, Roggla M, Kettenbach J, Dekan G, Locker GJ, Knapp S, Laczika K, Zimmerl M, Graninger W, Frass M (1997) Respiratory failure in systemic lupus erythematosus: decisive differentiation between acute pneumonitis and infection. Br J Rheumatol 36:295-297
71. Tanaka F, Origuchi T, Migita K, Tominaga M, Kawakami A, Kawabe Y, Eguchi K (2000) Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med 39:428-430
72. Tomioka R, King TE Jr (1997) Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease. Am J Respir Crit Care Med 155:1011-1020
73. Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, Baker S, Burt RK (2000) Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 356:701-707
74. Vachiery JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R (2002) Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 121:1561-1565
75. Varai G, Earle L, Jimenez SA, Steiner RM, Varga J (1998) A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 25:1325-1329
76. Vassallo R, Matteson E, Thomas CF Jr (2002) Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 122:1093-1096
77. Veeraraghavan S, Sharma OP (1998) Progressive systemic sclerosis and the lung. Curr Opin Pulm Med 4:305-309
78. Wang DY (2002) Diagnosis and management of lupus pleuritis. Curr Opin Pulm Med 8:312-316
79. Warrington KJ, Moder KG, Brutinel WM (2000) The shrinking lungs syndrome in systemic lupus erythematosus. Mayo Clin Proc 75:467-472
80. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947-954
81. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218-1222
82. Yigla M, Simsolo C, Goralnik L, Balabir-German A, Nahir AM (2002) The problem of empyematous pleural effusion in rheumatoid arthritis: report of two cases and review of the literature. Clin Rheumatol 21:180-183
83. Zamora MR, Warner ML, Tuder R, Schwarz MI (1997) Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 76:192-202
84. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH (1999) A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 341:1264-1269